Trilaciclib was approved by the U.S. Food and Drug Administration (FDA) on February 12, 2021.

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that the European Commission has granted approval for Dupixent (dupilumab) as an additional maintenance therapy for adults with uncontrolled chronic obstructive pulmonary disease with elevated blood eosinophils.

Evinacumab was approved by the U.S. Food and Drug Administration (FDA) on February 11, 2021.

Cartesian Therapeutics, revealed that the initial patient has been treated in its Phase 2 open-label clinical study assessing Descartes-08 in individuals with systemic lupus erythematosus.

Lisocabtagene maraleucel received approval from the U.S. Food and Drug Administration (FDA) on February 5, 2021.

Checkpoint Therapeutics has announced the successful resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for cosibelimab.

Voclosporin was approved by the U.S. Food and Drug Administration (FDA) on January 22, 2021.

BioCity reveals SC0062, an endothelin receptor A selective antagonist, has achieved its main objective in a Phase 2 study (2-SUCCEED) for IgA nephropathy. The trial was randomized, double-blind, and placebo-controlled.

Vericiguat received approval from the U.S. Food and Drug Administration (FDA) on January 19, 2021.

Epsilogen reveals CTA green light for Phase Ib study of MOv18 IgE in platinum-refractory ovarian cancer.

Ansuvimab-zykl (Ebanga) was approved by the US Food and Drug Administration (FDA) on December 21, 2020, for the treatment of Zaire ebolavirus infection in both adults and pediatric patients.

CSL Behring Treats First Hemophilia B Patients in Europe with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy.